Safety evaluation of the SAG2 rabies virus mutant in Tunisian dogs and several non-target species.
The safety of the SAG2 rabies virus, a highly attenuated mutant of the SAD strain intended to vaccinate dogs by the oral route, was evaluated in local Tunisian dogs and in five other local species likely to consume vaccine baits. These species were the domestic cat (Felis catus), the jackal (Canis aureus), the jerboa (Jaculus orientalis), the merion (Meriones sp.) and the gerbil (Gerbillus campestris). The vaccine was administered orally to 21 dogs, 11 cats and eight jackals and orally or intramuscularly to 62 wild rodents of the above-mentioned species. Seven dogs, one cat, five jackals all juvenile and with poor health status) and two rodents died for intercurrent causes. The others were observed for 60-180 days. No animal showed any rabies symptom. Seroneutralizing antibodies were observed in all experimental groups, only after vaccination, with the highest rate being observed in jackals and rodents. The rabies virus was detected in the oral cavity of three cats 6 h after oral instillation, but was not isolated later either in saliva or in salivary glands. Tissue samples (brain and salivary glands) from dead or euthanized animals were examined for the rabies virus antigen by a fluorescent antibody test. No rabies antigen was detected. These trials confirm the safety of the SAG2 strain on the Tunisian species already demonstrated by other authors on many other target and non target species.
Hammami
S
S
Laboratoire de virologie, Institut de la recherche vétérinaire de Tunisie, Tunis, Tunisia.
Schumacher
C L
CL
Cliquet
F
F
Barrat
J
J
Tlatli
A
A
Ben Osman
R
R
Aouina
T
T
Aubert
A
A
Aubert
M
M
D000284:Administration, Oral; D000821:Animal Feed; D000818:Animals; D000914:Antibodies, Viral / Q000097:blood; D002335:Carnivora; D002415:Cats; D004285:Dogs; D005849:Gerbillinae; D011819:Rabies Vaccines / Q000008:administration & dosage / Q000009:adverse effects*; D011820:Rabies virus / Q000235:genetics / Q000302:isolation & purification*; D012449:Safety; D012463:Saliva / Q000821:virology; D013045:Species Specificity; D014416:Tunisia; D014613:Vaccines, Attenuated / Q000008:administration & dosage / Q000009:adverse effects*
D000914:Antibodies, Viral; D011819:Rabies Vaccines; D014613:Vaccines, Attenuated